• Evaluation the Effect of different concentrations at48hour Mercaptopurine (6-MP) on Expression Changes of CPEB2 in Jurkat E6.1 cell line
  • Arezoo Hassani,1 Mahnaz Eskandari,2 Golnaz Asaadi Tehrani,3,* Sina Mirza Ahmadi,4
    1. Msc of Molecular Genetic Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
    2. Msc of Molecular Genetic Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
    3. Assistant professor of Molecular Genetics, Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
    4. Assistant professor of Molecular Genetics Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran


  • Introduction: In acute lymphoblastic leukemia (ALL), early lymphoid pioneer cells multiply and take the place of healthy hematopoietic cells in the bone marrow. A purine analog called mercaptopurine (6-MP) is used to treat autoimmune disorders and leukemia. It has both immunosuppressive and anticancer properties. The cytoplasmic polyadenylation element binding protein (CPEB), an mRNA-binding protein that controls cytoplasmic polyadenylation of mRNA as a trans factor in oogenesis and spermatogenesis, is very similar to the protein that this gene encodes. Studies on a related mouse gene suggested that this protein may have a role in transcriptionally inactive haploid spermatids. This investigation looked at how 6-mp altered the acute lymphoblastic leukemia Jurkat E6.1 cell line's expression of CPEB2.
  • Methods: 6-MP was prepared at dosages of 5 and 10 µM in this investigation. The Jurkat E6.1 (T-ALL) cell after cell passage was bought from the Pasteur Institute of Iran at the passage and treated by 6-MP for 48 hours at the indicated concentrations. The expression variations of CPEB2 and the housekeeping GAPDH gene were then assessed by Real-Time PCR, and the results of Real-Time PCR were analyzed by Rest 2002 Software. Next, RNA extraction and cDNA synthesis were carried out.
  • Results: According to our research, the expression of CPEB2 was significantly decreased after 48 hours of treatment with 6-mp at 5 µM compared to non-6-mp samples and GAPDH. According to the findings, a concentration of 5 M at 48 h was the best dose and time. At 48 hours, the expressions of CPEB2 at 5 and 10 µM dosages were 0.787 and 1.811, respectively (p-value < 0.001).
  • Conclusion: It may be inferred from the analysis of CPEB2 expression variations after treatment with 6-MP that a concentration of 5 µM was successful in suppressing CPEB2 expression. The findings revealed that the most potent concentration of the medication, 5µM 6-MP, caused a further drop in the expression of CPEB2. Over 48 hours, 6-mp had a good impact on the CPEB2 oncogene reduction process. At some of the concentrations examined, this reduction in expressions was statistically significant. Decreased gene expression at the concentration of 5µM demonstrated that the effect of the drug was dependent on concentration and with increasing dose of the drug; a decreasing gene expression was evident. The result suggests that 6-MP has a high potential for controlling and treating cancers.
  • Keywords: Acute Lymphoblastic Leukemia, CPEB2, GAPDH, Mercaptopurine 6-MP